Vermont Public is independent, community-supported media, serving Vermont with trusted, relevant and essential information. We share stories that bring people together, from every corner of our region. New to Vermont Public? Start here.

© 2024 Vermont Public | 365 Troy Ave. Colchester, VT 05446

Public Files:
WVTI · WOXM · WVBA · WVNK · WVTQ
WVPR · WRVT · WOXR · WNCH · WVPA
WVPS · WVXR · WETK · WVTB · WVER
WVER-FM · WVLR-FM · WBTN-FM

For assistance accessing our public files, please contact hello@vermontpublic.org or call 802-655-9451.
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

The home for VPR's coverage of health and health industry issues affecting the state of Vermont.

FDA Approves Controversial New Painkiller

A controversial, super-potent new painkiller has received Food and Drug Administration approval and could be available this month.

It’s called Zohydro, and it promises to relieve severe pain in patients who cannot get relief from other medications. But it’s sold in an easy-to-crush capsule. And that makes it easy to abuse. Congressman Peter Welch, along with other lawmakers and law enforcement officials, wants the FDA to reverse its approval.

“So the question we have is, if you’re going to use this drug, have the manufacturer of  ZOHYDRO do what the Oxycontin manufacturer did and put it out in a tamper-resistant form, and that means that potential abusers wouldn’t be so easily able to crush it, snort it chew it or inject it," Welch said. 

Welch worries that Zohydro will worsen the opioid epidemic sweeping through Northern New England.

But rival drug maker Oxycontin has just announced that it has finished testing a tamper resistant form of the new controversial painkiller. So Zohydro may have some stiff competition, in the long run.

Charlotte Albright lives in Lyndonville and currently works in the Office of Communication at Dartmouth College. She was a VPR reporter from 2012 - 2015, covering the Upper Valley and the Northeast Kingdom. Prior to that she freelanced for VPR for several years.
Latest Stories